ReviewClinical pharmacology and therapeutics2007
The pharmacogenetics research network: from SNP discovery to clinical drug response.
Review in Clinical pharmacology and therapeutics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 1 synthesis or guideline pooled it, 243 citations in OpenAlex.
- An in silico model using prognostic genetic factors for ovarian response in controlled ovarian stimulation: A systematic review.Journal of assisted reproduction and genetics · 2021Pooled it
- Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects.Clinical drug investigation · 2015Trial
- DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy.Medical oncology (Northwood, London, England) · 2012Trial
- A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.Investigational new drugs · 2012Trial
- Dopamine genes and nicotine dependence in treatment-seeking and community smokers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2009Trial
- ETV1 genetic polymorphisms as a candidate prognosis biomarker of Gastrointestinal stromal tumor.Cancer chemotherapy and pharmacology · 2025Article
- Leading the Way: Multi-Drug Resistance Protein (MDR1) and Clinical Pharmacology-Commentary on Kim et al.Clinical pharmacology and therapeutics · 2025Article
- Bioinformatic challenges for pharmacogenomic study: tools for genomic data analysis.Frontiers in pharmacology · 2025Article
- Targeting CD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies.International journal of molecular sciences · 2024Review
- Article
- An Exploratory Application of Multilayer Networks and Pathway Analysis in Pharmacogenomics.Genes · 2023Article
- Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide.Human genetics · 2022Review
- PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge.Current protocols · 2021Article
- Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children's Genomic Medicine Consortium.The pharmacogenomics journal · 2021Review
- Transcription-translation error:Informatics in medicine unlocked · 2021Article
- Genetic polymorphisms influence gene expression of human periodontal ligament fibroblasts in the early phases of orthodontic tooth movement.Odontology · 2020Article
- Pharmacogenomics in pregnancy.Seminars in perinatology · 2020Review
- The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics.Neuropharmacology · 2019Review
- In Silico Analysis of Coding/Noncoding SNPs of HumanJournal of diabetes research · 2019Article
- A framework for enhancing ethical genomic research with Indigenous communities.Nature communications · 2018Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 16 institutions in 2 countries.
Funding
Abstract
The NIH Pharmacogenetics Research Network (PGRN) is a collaborative group of investigators with a wide range of research interests, but all attempting to correlate drug response with genetic variation. Several research groups concentrate on drugs used to treat specific medical disorders (asthma, depression, cardiovascular disease, addiction of nicotine, and cancer), whereas others are focused on specific groups of proteins that interact with drugs (membrane transporters and phase II drug-metabolizing enzymes). The diverse scientific information is stored and annotated in a publicly accessible knowledge base, the Pharmacogenetics and Pharmacogenomics Knowledge base (PharmGKB). This report highlights selected achievements and scientific approaches as well as hypotheses about future directions of each of the groups within the PGRN. Seven major topics are included: informatics (PharmGKB), cardiovascular, pulmonary, addiction, cancer, transport, and metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.